Eli Lilly: liver cancer drug succeeds in late-stage trial
(CercleFinance.com) - Lilly's Cyramza has met its primary endpoint of overall survival, as well as the secondary endpoint of progression-free survival, in patients with advanced liver cancer, an aggressive disease that has a poor prognosis, the company said on Wednesday.
Cyramza has now demonstrated a survival benefit in four aggressive, difficult-to-treat tumour types in Phase 3 studies, including non-small cell lung and colorectal cancer, one of the world's main causes of cancer, the group said.
Lilly intends to initiate regulatory submissions in mid-2018.
The US drugmaker also said on Wednesday that it has signed a strategic collaboration with Sigilon Therapeutics to develop encapsulated cell therapies for the treatment of type 1 diabetes.
Cambridge, Massachusetts-based Sigilon will receive an upfront payment of 63 million dollars, as well as an undisclosed equity investment.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Cyramza has now demonstrated a survival benefit in four aggressive, difficult-to-treat tumour types in Phase 3 studies, including non-small cell lung and colorectal cancer, one of the world's main causes of cancer, the group said.
Lilly intends to initiate regulatory submissions in mid-2018.
The US drugmaker also said on Wednesday that it has signed a strategic collaboration with Sigilon Therapeutics to develop encapsulated cell therapies for the treatment of type 1 diabetes.
Cambridge, Massachusetts-based Sigilon will receive an upfront payment of 63 million dollars, as well as an undisclosed equity investment.
Copyright (c) 2018 CercleFinance.com. All rights reserved.